- Conditions
- Migraine
- Interventions
- Ubrogepant, Erenumab, Galcanezumab
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 2
- States / cities
- Springfield, Missouri • West Bend, Wisconsin
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–45
of 21
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis
- Interventions
- Ubrogepant, Rimegepant, Atogepant, Eptinezumab, Fremanezumab, Galcanezumab, Erenumab, Botulinum toxin A
- Drug
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Migraine
- Interventions
- Aimovig
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 1,839 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Vasomotor Symptoms; Hot Flashes
- Interventions
- Erenumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 45 Years to 65 Years · Female only
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 7
- States / cities
- San Diego, California • Miami, Florida • Winston-Salem, North Carolina + 3 more
- Conditions
- Posttraumatic Headache, Mild Traumatic Brain Injury
- Interventions
- Erenumab 140 Mg/mL Subcutaneous Solution, Placebo
- Drug
- Lead sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 4
- States / cities
- Fort Bragg, North Carolina • Pittsburgh, Pennsylvania • El Paso, Texas + 1 more
- Conditions
- Migraine
- Interventions
- Galcanezumab
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Cranial Nerve Injury, Oropharyngeal Cancer
- Interventions
- Prednisone, Ajovy, Manual Therapy, IOPI device
- Drug · Other · Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Fibromyalgia
- Interventions
- Erenumab, Saline
- Drug
- Lead sponsor
- United States Naval Medical Center, Portsmouth
- Federal
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Portsmouth, Virginia
- Conditions
- Vestibular Migraine
- Interventions
- Galcanezumab Prefilled Syringe, Placebo
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Temporomandibular Disorder
- Interventions
- Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments, Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments
- Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 59 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Temporomandibular Disorders
- Interventions
- Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe, Placebo
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Migraine
- Interventions
- Erenumab-Aooe 140 MG/ML [Aimovig]
- Drug
- Lead sponsor
- Merle Diamond
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • City of Saint Peters, Missouri • Springfield, Missouri
- Conditions
- Treatment for Prevention of Chronic Migraine
- Interventions
- Erenumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 609 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 29
- States / cities
- Newport Beach, California • Palo Alto, California • Santa Monica, California + 25 more
- Conditions
- Migraine
- Interventions
- Erenumab
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Stable Angina
- Interventions
- Erenumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Jacksonville, Florida • Miami, Florida • Atlanta, Georgia + 5 more
- Conditions
- Migraine
- Interventions
- Eptinezumab, Erenumab, Onabotulinumtoxin-A, Fremanezumab, Galcanezumab
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 10
- States / cities
- Gilbert, Arizona • Stamford, Connecticut • Palmetto Bay, Florida + 7 more
- Conditions
- Migraine, Episodic Migraine, Chronic Migraine, Headache
- Interventions
- CGRP antibody or gepant
- Drug
- Lead sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Post-Traumatic Headache
- Interventions
- Erenumab, Placebo
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more
- Conditions
- Schwannomatosis, Schwannomas, Pain, Chronic
- Interventions
- Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo, Erenumab-Aooe Matching Placebo
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Migraine
- Interventions
- Erenumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Fullerton, California + 38 more
- Conditions
- Status Migrainosus
- Interventions
- Erenumab
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona